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Abstract
Background: The incidence of hepatocellular carcinoma (HCC) and its association with hepatitis C (HCV) and
hepatitis B virus (HBV) infections, FIB-4 index and liver enzymes was assessed in an area of the province of Naples
covered by a population-based cancer registry.
Methods: We conducted a cohort investigation on 4492 individuals previously enrolled in a population-based
seroprevalent survey on HCV and HBV infections. The diagnosis of HCC was assessed through a record linkage with
the cancer registry. Hepatic metabolic activity was measured through serum alanine transaminase, aspartate
aminotransferase, gamma-glutamyl-transferase, and platelet. The FIB-4 index was used as a marker of fibrosis. We
computed HCC incidence rates (IR) for 100,000 (105) person-years of observation, and multivariable hazard ratios
(HR) with 95 % confidence intervals (CI) to assess risk factors for HCC.
Results: Twenty two cases of HCC were diagnosed during follow-up (IR = 63.3 cases/105). Significantly increased
HCC risks were documented in individuals with higher than normal liver enzymes and low platelet count; in the
239 HCV RNA-positives (HR = 61.8, 95 % CI:13.3–286); and in the 95 HBsAg-positives (HR = 75.0) –as compared to
uninfected individuals. The highest FIB-4 score was associated with a 17.6-fold increased HCC risk.
Conclusions: An elevated FIB-4 index turned out to be an important predictor of HCC occurrence. Although the
standard method to assess hepatic fibrosis in chronic hepatitis remains the histologic staging of liver biopsy
specimen, the assessment of FIB-4 in HCV RNA-positive individuals may help in identifying the highest HCC-risk
individuals who need anti-HCV treatment most urgently.
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Background
Hepatocellular carcinoma (HCC) - the fifth most com-
mon cancer in men (554,000 cases, 7.5 % of the total
burden of cancer) and the ninth in women (228,000
cases, 3.4 %) worldwide - represents an important public
health issue. The HCC burden is particularly heavy in
less developed countries, where 83 % of the estimated
782,000 new HCC cases worldwide were diagnosed in
2012 [1]. Within the World Health Organization
(WHO) European region, one of the highest HCC inci-
dence rates is registered in southern Italy, mostly be-
cause of an epidemic in the Campania region, with
yearly rates as high as 48.3 HCC cases/100,000 in men
and 18.4/100,000 in women [2–4].
Infection with hepatitis C virus (HCV) and/or hepatitis
B virus (HBV) are major risk factors for HCC [5, 6].
Worldwide, the estimated prevalence of HCV infection
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is about 2.2 %, with regional variations ranging from
<1.0 % in northern Europe to >3 % in northern Africa.
Within Europe, the lowest prevalence of HCV infection
was reported in the United Kingdom and Scandinavia
(0.01–0.1 %), and the highest one in southern Italy
(7.5 %) [6].
In Italy, population-based sero surveys showed a
strong North–south geographic gradient [7–10], with
high prevalence of HCV in the southern part of the
country. In this area, particularly elevated HCV preva-
lence rates were recorded among the older segment of
the population (23 % of people aged 65 or more was
HCV-positive in a population-based investigation con-
ducted by our study group between 2003 and 2006) [11,
12]. Chronic HCV infection (i.e., HCV RNA–positivity)
is more common than chronic HBV infection, and high
HCV prevalence is mainly due to iatrogenic transmis-
sion in the past decades [12].
An estimated 55–85 % of people with HCV infection
progress to chronic HCV infection, a condition that puts
these people at risk of liver cirrhosis, liver failure or HCC
at varying rates according to factors such as age, male sex,
presence of other risk factors (e.g., alcohol), or to viral in-
fections and metabolic characteristics [5, 6, 13, 14]. Liver
fibrosis is a major negative prognostic marker, and the de-
gree of histologic fibrosis in a liver biopsy sample is still
the most common tool for staging liver diseases associated
with HCV and/or HBV infections. However, such diagnos-
tic procedure is affected by several drawbacks, and non-
invasive serum markers have been proposed and validated
to predict the progression of liver fibrosis, including the
FIB-4 index -described in the Methods section [15–17].
In this study, we took advantage of a population-based
cohort whose baseline HBV and HCV seroprevalence
was evaluated between 2003 and 2006 in the province of
Naples, an area of southern Italy covered by a
population-based cancer registry and with high inci-
dence rates of HCC [11]. The main aims of this analysis
were to estimate incidence and determinants of newly
diagnosed HCC cases among the cohort members with
special emphasis on the consequences of HCV RNA-
positivity- and the role of FIB-4 as an index of hepatic fi-
brosis in HCC.
Methods
Study design and population
The design of this population-based investigation is
longitudinal. Our study took place in an area of the
province of Naples, southern Italy, with about 650,000
inhabitants who are covered by a population-based
cancer registry – the Campania Cancer Registry (CCR).
The enrollment in this population-based seropreva-
lence survey took place in 2003–2006, when 4496 indi-
viduals aged 20 years or older were randomly selected
(after stratification for sex and age) from the resident
population [11]. At enrolment, study participants were
interviewed, blood sample taken and tested for HCV
and HBV infections and for hepatic metabolic activity.
Among these 4496 individuals, 336 were anti-HCV pos-
itives and 100 were HBsAg-positives, and they were the
main target of this follow-up analysis.
Inclusion criteria
For the aims of this cohort analysis, we excluded four of
the 4496 individuals tested in 2003–2006 because they
had been already diagnosed with HCC at enrolment (i.e.,
they were prevalent HCC cases).
Data collection
A semi-automated, anonymous record linkage was carried
out in October 2014 by means of a previously validated
record linkage procedure [18]. We linked the database of
the seroprevalence study and the database of the
population-based CCR. HCC at CCR were identified ac-
cording to International Classification of Diseases, 10th re-
vision [19] and International Classification of Diseases for
Oncology (ICDO, C22.0-C22.9 codes) [20]. Individual data
regarding the occurrence of new HCC diagnoses and vital
status were updated to December 2012 (last date of cancer
registration).
Serum alanine transaminase (ALT), aspartate amino-
transferase (AST), gamma-glutamyl transferase (γGT),
and platelets counts were measured at enrolment with
upper normal limits (UNL) of 40 U/L for AST and ALT;
and 30 U/L for γGT [11].
To assess liver fibrosis, we used the FIB-4 index, com-
puted according to the following formula [15]: FIB-4 =
age [years] × AST [U/L]/(platelets [109/L] × √ALT [U/L]).
The FIB-4 values were divided into three groups/tertiles
in order to make our results comparable with those
already described in the literature [15–17]: FIB-4 <1.45,
the lowest tertile, which identifies subjects without liver
fibrosis; FIB-4 between 1.45 and 3.25, the intermediate
tertile, which identifies subjects with mild to moderate
fibrosis; and FIB-4 >3.25, the highest tertile, which iden-
tifies subjects with severe fibrosis.
Among the 4492 individuals included in this cohort
analysis, 99 were chronically infected with HBV (i.e.,
they were HBsAg-positives); 243 were chronically in-
fected with HCV (i.e., they were HCV RNA-positives);
and 89 were anti HCV-positives but HCV RNA-
negatives. Four individuals HBsAg-positives were also
HCV RNA-positives (Fig. 1).
Statistical analysis
Person-years (PY) at risk of HCC were computed from
date of testing to date of HCC diagnosis; date of death
or December 31, 2012, whichever occurred first.
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Incidence rates (IR) of HCC were computed by dividing
the number of new cancers by PY at risk. The associ-
ation between selected variables, collected at time of
testing, and the occurrence of HCC at follow-up was es-
timated by using the Cox multivariable regression ana-
lysis through the calculation of hazard ratios (HR) and
95 % CIs adjusted for sex, age, HBV and HCV infection.
The probability of surviving according to HCV infection
was computed according to the Kaplan-Meier method
[21].
All statistical analyses were performed using commer-
cially available software (SAS Institute Inc., version 9.4,
Cary, NC, USA; and STATA version 13, StataCorp LP,
College Station, Texas).
Results
The 4492 cohort members included in this study (44.7 %
men) had a median age of 45.7 years (interquartile range
-IQR: 30.5–60.3 years), and they had been followed up
for a median period of 8.0 years (IQR: 7.2–8.6 years).
The median time from testing to HCC diagnosis was
37 months, while the median age at HCC diagnosis was
73.3 years (data not shown).
Twenty-two cohort members developed HCC during the
34,749 PYs of follow-up: two were anti HCV-negatives and
HBsAg-negatives; 15 were HCV RNA-positives; three were
anti HCV-negatives and HBsAg-positives; and two were
anti HCV-positives/HCV RNA-negatives and HBsAg-
negatives.
Table 1 shows IRs and multivariate HRs for HCC
according to selected characteristics collected at base-
line. Overall, the IR of HCC was 63.3 cases/105 PY, and
the cumulative incidence at the end of the follow-up
period was 0.5 % (22/4492). Elevated HCC IRs were
recorded among subjects aged 60 years or older (252.8/
105 PY in those ≥70 years), in HCV RNA-positives/
HBsAg-negatives (909.3/105 PY), and in HBsAg-positive/
HCV-negative individuals (403.3/105 PY). IRs of HCC
were highly increased in cohort members with liver
markers exceeding by three or more times the normal
level, i.e., 1598 HCC cases/105 PY for ALT; 3539
cases/105 PY for AST; and 1006 cases/105 PY for
γGT. Similarly, individuals with the highest tertile of
FIB-4 index (i.e., >3.25) showed a very high IR of
HCC, 1889 cases/105 PY (Table 1). Eighty-nine anti
HCV-positive/HCV RNA-negative individuals devel-
oped two HCC cases (IR = 296.0, 95 % CI: 74.0–1184)
(data not shown).
At multivariable analysis, statistically significant risk
factors for HCC included age ≥60 years, HCV RNA-
positivity (HR = 61.8), HBsAg-positivity (HR = 75.0),
elevated values of markers of hepatic metabolic activity,
with elevated risks (highest versus normal level) ranging
from 10-fold for γGT to 50-fold for platelet below 220.
Increasing values of FIB-4 index were associated with
increasing HCC risks – e.g., the highest FIB-4 tertile was
coupled with a 17.6-fold higher risk of HCC, as
compared to cohort members with lower values (95 % CI:
6.2–49.7) (Table 1).
The distribution of cohort members according to
chronic HCV infection, FIB-4 index and HCC is de-
scribed in Table 2. HCV infection and FIB-4 index were
strongly associated: 59.1 % of individuals with the high-
est FIB-4 tertile (68/115) were chronically infected with
HCV, as compared to 15.4 % (110/714) of individuals
with the intermediate FIB-4 tertile, and 1.8 % for those
with the lowest FIB-4 tertile. The HR of HCC directly
increased with increasing values of FIB-4, in both anti
HCV-negatives and in HCV RNA-positives. In anti
HCV-negatives, HCC risk was 79-fold elevated (95 % CI:
4.9–1285) in those with the highest FIB-4 tertile –as
compared to the lowest one. Conversely, in HCV RNA-
positive cohort members, HCC risk was 771-fold higher
(95 % CI: 100–5949) in those with the highest FIB-4
tertile –as compared to the lowest one (Table 2). The
highest HCC cumulative incidence (17.4 % after 4 years
of follow-up) was recorded among HCV RNA-positives
with the highest FIB-4 tertile (Fig. 2).
Individuals tested for HBV and HCV infections
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Fig. 1 Distribution of cohort members according to HCV and HBV test results
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Furthermore, HCV-infection negatively affected the
survival of the cohort members: after 8 years of
follow-up, 94.6 % of the 4065 HCV-negatives was alive,
as compared to 71.5 % of HCV RNA-positive individuals
(p < 0.001) (Fig. 3).
Discussion
This population-based cohort study of individuals tested
for hepatitis viruses was conducted in an area of
southern Italy with one of the highest incidence rates of
HCC in Europe [1]. The study findings confirmed that
people chronically infected with HBV (i.e., HBsAg-
positive individuals) or HCV (i.e., anti HCV RNA–
positive individuals) are at a substantially higher risk of
HCC than uninfected ones. In addition, to substantiate
the well-established role of HCV on heightening the risk
of HCC, the study findings add further, population-
based evidence to the few studies that have already
Table 1 Distribution of 4492 study subjects by selected characteristics at enrolment; diagnosis of hepatocellular carcinoma (HCC) at
follow-up; HCC incidence rates and hazard ratios for HCC with 95 % confidence intervals (CI). Naples, 2003–2012
Characteristics at enrolment Study subjects HCC cases Incidence Rate/105
(95 % CI)
Hazard Ratios
(95 % CI)bNo. No.
Total 4492 22 63.3 (41.7–96.2)
Gender
Female 2482 10 51.4 (27.6–95.5) 1*
Male 2010 12 78.5 (44.6–138.3) 1.2 (0.5–2.7)
Age at testing (years)
< 60 3349 3 11.3 (3.6–35.0) 1*
60–69 551 9 214.7 (111.7–412.6) 7.5 (1.8–30.8)
≥ 70 592 10 252.8 (136.0–469.8) 6.8 (1.6–29.3)
Chronic HCV/HBV infections**
Anti HCV-negative/HBsAg-negative 4065 2 6.3 (0.8–22.8) 1*
HCV RNA-negative/HBsAg-positive 95 3 403.3 (83.2–1179) 75.0 (12.3–456.5)
HCV RNA-positive/HBsAg-negative 239 15 909.3 (509.0–1500) 61.8 (13.3–286.4)
HCV RNA-positive/HBsAg-positive 4 0 0.0 (0.0–11,938) 0.0 (0.0-∞)
γ-glutamyl transferase (γGT) U/La
≤ 30 3588 9 32.2 (16.8–61.9) 1*
31–90 784 5 83.9 (34.9–201.6) 1.5 (0.5–4.7)
> 90 116 8 1006 (503.0–2011) 10.3 (3.6–29.2)
Alanine transaminase (ALT) U/La
≤ 40 3954 8 26.1 (13.1–52.2) 1*
41–120 490 9 240.1 (125.0–461.5) 4.1 (1.5–11.4)
> 120 45 5 1598 (665–3840) 10.3 (3.2–33.3)
Aspartate aminotransferase (AST) U/La
≤ 40 4294 6 18.0 (8.1–40.0) 1*
41–120 170 11 885.1 (490.2–1598) 9.4 (3.1–28.8)
> 120 25 5 3539 (1473–8501) 27.4 (7.6–98.0)
Platelet count (103/μl)a
220–700 2253 2 11.4 (1.4–41.1) 1*
< 220 2203 20 118.4 (72.3–182.8) 50.0 (1.0–100.0)
FIB-4a
< 1.45 3552 1 3.6 (0.5–25.4) 1*
1.45–3.25 774 5 88.3 (36.8–212.2)
> 3.25 130 16 1889 (1157–3083) 17.6 (6.2–49.7)
aThe sum does not add up to the total because of missing values; badjusted for gender, age, chronic HCV/HBV infections – except FIB-4, which was adjusted for
gender and chronic HCV/HBV infections since age is included in the index; *reference category; **89 HCV-positive, RNA-negative study subjects who developed 2
HCC cases were excluded
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documented the prognostic value of the FIB-4 index as a
non-invasive screening tool for HCC.
Early detection of HCC has remarkable survival advan-
tages, and the efficacy of HCC screening is a matter of
debate with particular regard to the role of non-invasive
screening tools as alternative to, or in combination with,
liver biopsy and fibroscan [22, 23]. A recent meta-
analysis of studies carried out in patients with chronic
HBV infection highlighted a modest diagnostic accuracy
and sensitivity of the FIB-4 index for predicting liver fi-
brosis in these patients [24]. Conversely, in a cohort
study involving 986 Korean HBsAg carriers, the FIB-4
index was shown to have a valuable role in HCC screen-
ing, as HBsAg carriers with high FIB-4 index were at
very high risk of HCC [25]. High levels of FIB-4 were
also significantly predictive of HCC among moderate or
heavy alcohol drinkers [26], and among HIV-infected pa-
tients [27].
The FIB-4 index was firstly proposed to assess the
presence of liver fibrosis in patients with HCV/HIV co-
infection [28] and, subsequently, it was validated in a
cohort of HCV-infected patients in France [15], and in a
large cohort in the United States. FIB-4 was shown to be
a valid parameter for staging liver disease and monitor-
ing HCV-infected patients in longitudinal studies [16].
Since advanced fibrosis is among the most important in-
dicators in stratifying patients with chronic HCV infec-
tion for retreatment, Tanwar and colleagues [29]
compared the performance of ten biomarkers of fibrosis
among patients with chronic HCV and treatment failure.
They assessed the impact on biomarker performance of
two different assays of hyaluronic acid. Although many
biomarkers exhibited good diagnostic performance for
the detection of advancing fibrosis, the study findings
highlighted a potential drawback, since the diagnostic
performance was significantly affected by the selection
of individual component assays [29].
In the French cohort, FIB-4 values lower than 1.45 had
a negative prognostic value of 94.7 % of excluding a severe
fibrosis, while a value higher than 3.25 had a positive pre-
dictive value of 82.1 % [15]. Accordingly, the findings from
this cohort study highlighted that individuals with a value
Time since blood tests (years)























HCV-positive, any FIB-4 level
FIB-4  1.45-3.25
FIB-4  <1.45
FIB-4 > 3.25 68 58 49 36 24
FIB-4  1.45-3.25 110 105 101 91 53
HCV-positive, any FIB-4 level 239 221 207 182 106
FIB-4  <1.45 61 58 57 55 29
No. at risk
Fig. 2 Incidence of hepatocellular carcinoma among HCV RNA-positive/HBsAg-negative subjects
Table 2 Hazard ratios (HR) with 95 % confidence intervals (CI) for hepatocellular carcinoma (HCC) among 4270a study subjects,
according to HCV RNA-positivity and FIB-4 index. Naples, 2003–2012
HCV
RNA













HRb (95 % CI)
Negative 3380 1 (0.03) 1* 604 0 (0.0) 0 (0-∞) 47 1 (2.1) 79.5 (4.9–1285)
Positive 61 0 (0.0) 0 (0-∞) 110 3 (2.7) 99.5 (10.3–957.3) 68 12 (17.6) 771.2 (100.0–5949)
a99 HBsAg-positive and 89 anti-HCV-positive, HCV-RNA-negative study subjects were excluded. Information on FIB-4 index was not available for 34 remaining
study subjects
bHazard ratios adjusted for gender
*Reference category
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of FIB-4 index higher than 3.25 were at a 17-fold elevated
HCC risk – as compared to those with lower values of
FIB-4. In particular, the highest HCC incidence was re-
corded among chronically HCV-infected cohort members
with the highest FIB-4 tertile. An increased incidence of
HCC was also noted in individuals with intermediate FIB-
4 tertile, thus our findings point to a significant predictive
role of FIB-4 in identifying individuals at high risk of
HCC.
In the area where the present study was conducted,
more than 90 % of HCC cases were attributable to HCV
and/or HBV infections, and the remaining to alcohol in-
take (6 %), smoking or other risk factors [30]. Accord-
ingly, only two of the 22 HCC cases documented in this
cohort were not chronically infected with HCV or HBV,
whereas 15 were HCV chronic carriers and HBs-Ag-
negative.
In areas with high prevalence rates of HCV infection,
as the one where this cohort study was carried out, the
FIB-4 index of fibrosis seems to significantly improve
the early identification of individuals at higher risk of de-
veloping HCC. From this perspective, it is worth noting
that the time from FIB-4 measurement and HCC diag-
nosis decreased from 6.8 years in the HCC case with
FIB-4 value <1.45, to a median of 2.8 years among HCC
cases with a FIB-4 value higher than 3.25.
The rapid development of direct-acting antiviral
(DAA) agents for HCV infection has driven substantial
optimism on new therapeutic interventions, with regard
to improved efficacy, lower frequency of side effects, and
shorter duration than currently available therapies.
However, the potential effect of these new therapies is
limited because of lack of systematic screening for HCV
infection and the high cost of DAA. Among the mem-
bers of this cohort, at time of testing less than half (n =
149) of the 332 HCV-infected individuals was aware of
being infected, and only 42 of them (28.2 %) had already
received conventional interferon-based treatment. Given
the costs of DAA, there is heated debate on how to
prioritize patients to be treated with these drugs, with
European guidelines suggesting to privilege patients with
advanced liver disease for DAA therapies [31]. The find-
ings from this study may further help in addressing this
issue, by suggesting that people with chronic HCV infec-
tion with a value of FIB-4 index >3.25 are at elevated
risk of developing HCC in the next 4 years. Further-
more, people with chronic HCV infection with a value
of FIB-4 index ≥1.45 are at elevated risk of developing
HCC in the next 5–6 years.
It is worth stressing that these results derive from
about 8 years of follow-up of 4492 people living in an
area of southern Italy covered by a population-based
cancer registry – the CCR [32]. Completeness and
accuracy in the ascertainment of HCC cases occurring
in the cohort was thus ensured by the longitudinal
study design. Lack of information, at baseline, on some
variables known to be associated with HCC risk (e.g.,
alcohol intake), or at follow-up on determinants of
progression of liver disease (e.g., HCV treatment) needs
to be mentioned. Furthermore, a relative small number
of events limited the statistical power of sub-group ana-
lysis. Moreover, it was not feasible to estimate HCC risk
Time since blood tests (years)
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Fig. 3 Cumulative survival probability by chronic HCV infection among 4304 study subjects. Naples, 2003–2012. * 99 HBsAg-positive and 89 HCV-
positive, HCV-RNA-negative study subjects were excluded
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in HBsAg-positives and in anti HCV-positive/HCV
RNA-negative individuals because of a reduced statis-
tical power due to a small number of HCC diagnoses
(n = 3, and n = 2 –respectively).
In addition to the above discussed impact of HCV,
HBV and FIB-4 index of fibrosis, our findings from the
multivariable analysis confirmed the prognostic indica-
tion associated with other well established predictors of
HCC. Values of ALT, AST, and γGT higher than normal
were indeed associated with high risks of HCC even
after adjustment for HCV infection, HBV infection and
FIB-4 index.
Conclusions
Although the standard method to assess hepatic fibrosis
in chronic hepatitis remains the histologic staging of
liver biopsy specimen, findings from this population-
based cohort study support the results of the few studies
that have already documented a predictive role of FIB-4
index of fibrosis for HCC occurrence. This effect was
particularly evident in people with chronic HCV infec-
tion, thus offering new insights for identifying people at
high HCC risk worth to be prioritized for receiving anti-
HCV treatments.
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